Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
ONCOLOGY / BASIC RESEARCH
LncRNA MIR155HG functions as a ceRNA for inhibition of lung adenocarcinoma growth and prediction of prognosis
1
Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
Submission date: 2020-08-04
Final revision date: 2020-12-02
Acceptance date: 2020-12-04
Online publication date: 2021-02-09
Arch Med Sci 2024;20(2):539-556
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Long non-coding RNAs (lncRNAs) functioning as competing endogenous RNAs (ceRNAs) play critical roles in tumour progression. However, prognosis-related ceRNA networks in lung adenocarcinoma (LUAD) have not been well characterised.
Material and methods:
LUAD datasets were downloaded from the TCGA database, and the patients were divided into metastasis and non-metastasis groups. The differential expression of lncRNAs (DELs), miRNAs (DEMs), and mRNAs (DEGs) was analysed using the Limma package. Next, interactions between miRNA, lncRNA, and mRNA were predicted by miRcode, miRTarBase, miRDB, and TargetScan. The ceRNA network was constructed based on these interactions using Cytoscape software. DEG enrichment analysis was performed by GO and KEGG. After the prognosis analysis, we further screened molecules and constructed the prognosis-related ceRNA network. Moreover, the interactions between lncRNA, miRNA, and mRNA were validated by biological experiments.
Results:
854 DELs, 150 DEMs, and 2211 DEGs between metastasis and non-metastasis LUAD patients were identified. Functional enrichment analysis suggested that DEGs were closely related to key biological processes involved in LUAD progression. The prognosis-related ceRNA network included 1 miRNA, 2 lncRNAs, and 4 mRNAs. In this network, MIR155HG and ADAMTS9-AS2 can function as ceRNAs of miR-212 to regulate EPM2AIP1, LAX1, PRICKLE2, and CD226. Moreover, our study confirmed that MIR155HG inhibited the proliferation, migration, and invasion of LUAD cells by sponging miR-212-3p to regulate CD226.
Conclusions:
This ceRNA network contributes to understanding the pathogenesis of LUAD. Furthermore, the molecules in the network are valuable predictive factors for LUAD prognosis as well as potential therapeutic biomarkers.
Long non-coding RNAs (lncRNAs) functioning as competing endogenous RNAs (ceRNAs) play critical roles in tumour progression. However, prognosis-related ceRNA networks in lung adenocarcinoma (LUAD) have not been well characterised.
Material and methods:
LUAD datasets were downloaded from the TCGA database, and the patients were divided into metastasis and non-metastasis groups. The differential expression of lncRNAs (DELs), miRNAs (DEMs), and mRNAs (DEGs) was analysed using the Limma package. Next, interactions between miRNA, lncRNA, and mRNA were predicted by miRcode, miRTarBase, miRDB, and TargetScan. The ceRNA network was constructed based on these interactions using Cytoscape software. DEG enrichment analysis was performed by GO and KEGG. After the prognosis analysis, we further screened molecules and constructed the prognosis-related ceRNA network. Moreover, the interactions between lncRNA, miRNA, and mRNA were validated by biological experiments.
Results:
854 DELs, 150 DEMs, and 2211 DEGs between metastasis and non-metastasis LUAD patients were identified. Functional enrichment analysis suggested that DEGs were closely related to key biological processes involved in LUAD progression. The prognosis-related ceRNA network included 1 miRNA, 2 lncRNAs, and 4 mRNAs. In this network, MIR155HG and ADAMTS9-AS2 can function as ceRNAs of miR-212 to regulate EPM2AIP1, LAX1, PRICKLE2, and CD226. Moreover, our study confirmed that MIR155HG inhibited the proliferation, migration, and invasion of LUAD cells by sponging miR-212-3p to regulate CD226.
Conclusions:
This ceRNA network contributes to understanding the pathogenesis of LUAD. Furthermore, the molecules in the network are valuable predictive factors for LUAD prognosis as well as potential therapeutic biomarkers.
REFERENCES (30)
1.
Hayasaka K, Shiono S, Matsumura Y, et al. Epidermal growth factor receptor mutation as a risk factor for recurrence in lung adenocarcinoma. Ann Thorac Surg 2018; 105: 1648-54.
2.
Avancini A, Sartori G, Gkountakos A, et al. Physical activity and exercise in lung cancer care: will promises be fulfilled? Oncologist 2020; 25: e555-69.
3.
Huang HT, Xu YM, Ding SG, et al. The novel lncRNA PTTG3P is downregulated and predicts poor prognosis in non-small cell lung cancer. Arch Med Sci 2020; 16: 931-40.
4.
Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis 2018; 9: 117.
5.
de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Resh 2018; 7: 220-33.
6.
Arnold BN, Thomas DC, Rosen JE, et al. Lung cancer in the very young: treatment and survival in the National Cancer Data Base. J Thorac Oncol 2016; 11: 1121-31.
7.
Carnio S, Di Stefano RF, Novello S. Fatigue in lung cancer patients: symptom burden and management of challenges. Lung Cancer 2016; 7: 73-82.
8.
Yousem SA. Role of molecular studies in the diagnosis of lung adenocarcinoma. Modern Pathol 2012; 25 Suppl 1: S11-17.
9.
Cooke M, Baker MJ, Kazanietz MG. Rac-GEF/Rac signaling and metastatic dissemination in lung cancer. Front Cell Develop Biol 2020; 8: 118.
10.
Richardson AM, Havel LS, Koyen AE, et al. Vimentin is required for lung adenocarcinoma metastasis via heterotypic tumor cell-cancer-associated fibroblast interactions during collective invasion. Clin Cancer Res 2018; 24: 420-32.
11.
Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov 2013; 3: 1113-21.
12.
Li L, Wei J, Hei J, Ren Y, Li H. Long non-coding RNA H19 regulates proliferation of ovarian granulosa cells via STAT3 in polycystic ovarian syndrome. Arch Med Sci 2021; 17: 785-91.
13.
Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011; 146: 353-8.
14.
Liang W, Sun F. Competing endogenous RNA Network Analysis Reveals Pivotal ceRNAs in adrenocortical carcinoma. Front Endocrinol 2019; 10: 301.
15.
Chan JJ, Tay Y. Noncoding RNA:RNA regulatory networks in cancer. Int J Mol Sci 2018; 19: 1310.
16.
Wang J, Ding W, Xu Y, et al. Long non-coding RNA RHPN1-AS1 promotes tumorigenesis and metastasis of ovarian cancer by acting as a ceRNA against miR-596 and upregulating LETM1. Aging 2020; 12: 4558-72.
17.
Cai Y, Sheng Z, Chen Y, Wang J. LncRNA HMMR-AS1 promotes proliferation and metastasis of lung adenocarcinoma by regulating MiR-138/sirt6 axis. Aging 2019; 11: 3041-54.
18.
Ogunwobi OO, Kumar A. Chemoresistance mediated by ceRNA networks associated with the PVT1 locus. Front Oncol 2019; 9: 834.
19.
Li X, Li B, Ran P, Wang L. Identification of ceRNA network based on a RNA-seq shows prognostic lncRNA biomarkers in human lung adenocarcinoma. Oncol Letters 2018; 16: 5697-708.
20.
Peng L, Chen Z, Chen Y, Wang X, Tang N. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. Cancer Med 2019; 8: 7161-73.
21.
Morimoto K, Satoh-Yamaguchi K, Hamaguchi A, et al. Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs. Oncogene 2008; 27: 264-73.
22.
Wang F, Tang C, Xu D, et al. LncRNA ADAMTS9-AS2 suppresses the proliferation of gastric cancer cells and the tumorigenicity of cancer stem cells through regulating SPOP. J Cell Mol Med 2020; 24: 4830-8.
23.
Liu D, Wu K, Yang Y, Zhu D, Zhang C, Zhao S. Long noncoding RNA ADAMTS9-AS2 suppresses the progression of esophageal cancer by mediating CDH3 promoter methylation. Mol Carcinogen 2020; 59: 32-44.
24.
Li Y, Wan Q, Wang W, et al. LncRNA ADAMTS9-AS2 promotes tongue squamous cell carcinoma proliferation, migration and EMT via the miR-600/EZH2 axis. Biomed Pharmacother 2019; 112: 108719.
25.
Jin D, Song Y, Chen Y, Zhang P. Identification of three lncRNAs as potential predictive biomarkers of lung adenocarcinoma. BioMed Res Int 2020; 2020: 7573689.
26.
Deva Magendhra Rao AK, Patel K, Korivi Jyothiraj S, et al. Identification of lncRNAs associated with early-stage breast cancer and their prognostic implications. Mol Oncol 2019; 13: 1342-55.
27.
Rong HT, Liu DW. Identification of differentially expressed miRNAs associated with thermal injury in epidermal stem cells based on RNA-sequencing. Exp Ther Med 2020; 19: 2218-28.
28.
Fourcade J, Sun Z, Chauvin JM, et al. CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI insight 2018; 3: e121157.
29.
Peng YP, Xi CH, Zhu Y, et al. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. Oncotarget 2016; 7: 66586-94.
30.
Du X, de Almeida P, Manieri N, et al. CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1. Proc Natl Acad Sci USA 2018; 115: e11731-40.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
